-
A Study Of Tyrosine Kinase Inhibitor ICP-022 In Patients With R/r B-Cell Malignancies
Scottsdale/Phoenix, AZ; Rochester, MN
The main purpose of this study is to assess the maximal dose of ICP-022 that can be safely administered.
-
A Phase 1/2 Study Of STP938 For Adult Subjects With Relapsed/Refractory B-Cell And T-Cell Lymphomas
Scottsdale/Phoenix, AZ; Rochester, MN
The purpose of this study is to evaluate the safety and tolerability of STP938 as a single agent in adult subjects with R/R B-cell and T-cell lymphomas.
-
Exploring Mechanisms Of Action And Resistance Of Therapeutic Agents In Patients With B-cell Malignancies
Jacksonville, FL
This study is being performed to understand the causes of drug resistance and to improve the treatment options for patients diagnosed with B-cell cancers. We aim to identify the reasons why certain therapies work and others don’t and as result- develop new treatments for blood cancers.
-
Duvelisib And Nivolumab For The Treatment Of Stage IIB-IVB Mycosis Fungoides And Sezary Syndrome
Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN
This phase I trial identifies the best dose, possible benefits, and/or side effects of duvelisib in combination with nivolumab in treating patients with stage IIB-IVB mycosis fungoides and Sezary syndrome. Duvelisib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving duvelisib in combination with nivolumab may work better than giving each of these drugs individually, or treating with the usual approach in ...
-
Cutaneous Lymphoma Biobank Study
Scottsdale/Phoenix, AZ
The purpose of this study is to create a cutaneous lymphoma tissue repository. This is a highly significant first step in collecting specimens for future analysis to understand the underlying drivers of disease.